Cash and cash equivalents of $115.8 million at March 31, 2025 compared to $132.2 million at year ended September 30, 2024. As of quarter end, the Company anticipates at current cash utilization rates and ranges, a runway of approximately 4 years.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVXL:
- Largest borrow rate increases among liquid names
- Anavex Life Sciences (AVXL) Q2 Earnings Cheat Sheet
- Anavex Life Sciences: Promising Developments and Strategic Growth Opportunities Justify Buy Rating
- Anavex announces full enrollment fo Phase 2 study of ANAVEX 3-71
- Anavex appoints Audrey Gabelle to Scientific Advisory Board